Can SLU-PP-332 actually replace exercise?

In mice, it activates many of the same molecular pathways as aerobic exercise — increased oxidative muscle fibers, enhanced mitochondrial function, improved endurance. But exercise has hundreds of effects beyond ERR activation (cardiovascular, neurological, hormonal, skeletal). SLU-PP-332 replicates part of the exercise response, not all of it. It's being studied more as a therapeutic for people who can't exercise (heart failure, severe obesity, immobility) than as a shortcut for healthy people.

How does SLU-PP-332 differ from other performance compounds?

Most performance compounds (steroids, SARMs, GH secretagogues) target muscle growth pathways. SLU-PP-332 targets metabolic fitness — the cellular machinery that uses oxygen, burns fat, and sustains endurance. It's more like endurance training than weight training in a pill. The closest comparison is the earlier exercise mimetic AICAR (AMPK activator).

Is SLU-PP-332 banned in sports?

Not yet explicitly listed by WADA, but anti-doping agencies are actively preparing. Two 2026 papers characterized SLU-PP-332 metabolites specifically for doping-control detection, signaling imminent prohibition. Athletes should treat it as prohibited under WADA's S0 (unapproved substances) category.

SLU-PP-332

A synthetic exercise mimetic that activates estrogen-related receptors (ERRs) to replicate the molecular effects of aerobic exercise — increasing endurance, fat oxidation, and mitochondrial function without physical activity.

PreliminaryLimited Data

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by Thomas Burris's lab at Saint Louis University. It is not a peptide — it's a small molecule — but has gained significant attention in the performance and longevity community as an "exercise in a pill." In mice, SLU-PP-332 activates the same genetic program that aerobic exercise turns on: it increases fatigue-resistant type IIa muscle fibers, boosts mitochondrial function, increases energy expenditure, enhances fatty acid oxidation, and improves exercise endurance on treadmill tests. Beyond muscle, it has shown remarkable effects in heart failure (improved ejection fraction and survival, published in Circulation) and kidney aging. Anti-doping agencies are already developing detection methods — two papers on identifying SLU-PP-332 metabolites for doping control were published in 2026.

Why People Talk About It

Exercise endurance enhancement without exercise

Preliminary

Metabolic syndrome and obesity treatment

Preliminary

Heart failure (improved ejection fraction and survival)

Preliminary

Age-related muscle atrophy and sarcopenia

Limited

Mitochondrial dysfunction reversal in aging

Preliminary

How It Works

SLU-PP-332 activates a family of receptors called ERRs (estrogen-related receptors) that serve as master switches for the genes your body turns on during aerobic exercise. When activated, these receptors increase mitochondrial activity (your cells' power plants), shift muscle fibers toward the fatigue-resistant type used for endurance, and ramp up fat burning — producing many of the metabolic benefits of a workout without the physical activity.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

No human safety data — preclinical onlyNo adverse effects reported in mouse studies at therapeutic doses

Cautions

• Not approved for human use — strictly a research compound
• No human clinical trials have been conducted
• Anti-doping agencies are developing detection methods (likely to be prohibited in sports)
• Gray market sources have unknown purity and composition
• Long-term effects of chronic ERR activation are unknown

What We Don't Know

All data is from mouse models. Whether ERR agonism translates to meaningful exercise-like benefits in humans is unproven. Chronic pan-ERR activation could have unintended effects given that ERRs regulate genes across multiple organ systems. The next-generation compound SLU-PP-915 (orally active) may be more clinically relevant but also lacks human data.

Published Research

8 studies

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

PreclinicalPMID: 41850449

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

Anti-DopingPMID: 41588687

An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.

PreclinicalPMID: 41421047

Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.

PreclinicalPMID: 40692696

Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

PreclinicalPMID: 37961903

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

PreclinicalPMID: 37739806

Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.

PreclinicalPMID: 37717940

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

PreclinicalPMID: 36988910

Mechanism of Action

SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors alpha, beta, and gamma (ERRα/β/γ), with highest potency for ERRα. ERRs are orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism — the core metabolic adaptations of aerobic exercise. In skeletal muscle, SLU-PP-332 induces an ERRα-dependent acute aerobic exercise genetic program, increasing type IIa oxidative muscle fibers and enhancing treadmill endurance in mice. It upregulates PGC-1α, SIRT1, ERRα, and FNDC5 (irisin precursor), while reducing lactate dehydrogenase release, ROS production, and cellular senescence markers. In metabolic syndrome models, it increased energy expenditure and fatty acid oxidation, reduced fat mass, and improved insulin sensitivity. In heart failure (pressure overload model), it significantly improved ejection fraction, reduced fibrosis, and increased survival — with ERRγ identified as the primary cardioprotective mediator. Multi-omics analysis confirmed activation of fatty acid metabolism and mitochondrial function gene networks. In aging kidney, it reversed mitochondrial dysfunction and inflammation.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

None. SLU-PP-332 has not entered human clinical trials. All evidence is from mouse models and cell culture. The next-generation orally active compound SLU-PP-915 may be closer to clinical development.

Animal / Preclinical

Strong and multi-organ. Exercise/muscle: increased type IIa oxidative fibers and enhanced treadmill endurance in mice (ACS Chemical Biology, 2023). Metabolic syndrome: reduced obesity, increased energy expenditure, improved insulin sensitivity in obese mice (J Pharmacol Exp Ther, 2024). Heart failure: improved ejection fraction, reduced fibrosis, increased survival in pressure overload model (Circulation, 2024). Kidney: reversed age-related mitochondrial dysfunction and inflammation (2023). Muscle atrophy: pilot study targeting age-related inactivity (2025).

Mechanistic Rationale

Strong. ERRs are well-established master regulators of mitochondrial biogenesis and oxidative metabolism. The connection between ERR activation and exercise adaptation is supported by extensive prior research on PGC-1α/ERR signaling. SLU-PP-332's effects are consistent with predicted ERR biology across multiple organ systems.

Forms & Administration

SLU-PP-332 has been administered via intraperitoneal injection in mouse studies. An orally active next-generation compound, SLU-PP-915, has been developed and published in 2026. Neither is available for human use. These are strictly research compounds not available through legitimate medical channels.

Use Cases & Evidence Levels

Exercise endurance enhancement without exercise

Preliminary30%

Metabolic syndrome and obesity treatment

Preliminary30%

Heart failure (improved ejection fraction and survival)

Preliminary30%

Age-related muscle atrophy and sarcopenia

Limited15%

Mitochondrial dysfunction reversal in aging

Preliminary30%

Safety Profile

Safety Information

Common Side Effects

No human safety data — preclinical onlyNo adverse effects reported in mouse studies at therapeutic doses

Cautions

• Not approved for human use — strictly a research compound
• No human clinical trials have been conducted
• Anti-doping agencies are developing detection methods (likely to be prohibited in sports)
• Gray market sources have unknown purity and composition
• Long-term effects of chronic ERR activation are unknown

What We Don't Know

Published Research

8 studies

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

PreclinicalPMID: 41850449

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

Anti-DopingPMID: 41588687

An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.

PreclinicalPMID: 41421047

Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.

PreclinicalPMID: 40692696

Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

PreclinicalPMID: 37961903

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

PreclinicalPMID: 37739806

Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.

PreclinicalPMID: 37717940

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

PreclinicalPMID: 36988910

Related Peptides

MOTS-c

Emerging

A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'

SS-31

Emerging

A mitochondria-targeted peptide in clinical trials for heart failure and mitochondrial diseases.

Humanin

Emerging

A mitochondria-derived peptide with cytoprotective properties, studied for neuroprotection, metabolic regulation, and anti-aging effects.

MK-677

Moderate

An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.

Follistatin

Emerging

A naturally occurring protein that inhibits myostatin (the muscle growth limiter), studied for dramatic muscle growth potential.

Quick Facts

Class: Exercise Mimetic
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 8PubMed

Also known as

ERR Pan-AgonistExercise Mimetic

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.